Component information
No US or EU label exists for this exact combination, so information is shown for each component.
Use: For management of mild to moderate pain in patient 14 years of age and older, when therapy will not exceed one week (7 days). US FDA label
Kidney dosing: Mefenamic acid (single-agent)Show full dosing details
- CrCl ≥60 mL/min
- 500 mg first dose, then 250 mg every 6 hours as needed; usually not beyond 1 week (label). Check kidney function before use if risk factors.
- CrCl 30–59 mL/min
- Label 8.6: should not be given to patients with pre-existing kidney disease or significantly impaired kidney function; metabolites (excreted mainly in urine) may accumulate. Not studied in kidney impairment.
- CrCl 15–29 mL/min
- Label 8.6: should not be given to patients with pre-existing kidney disease or significantly impaired kidney function; metabolites (excreted mainly in urine) may accumulate. Not studied in kidney impairment.
- CrCl <15 mL/min (not on dialysis)
- Label 8.6: should not be given to patients with pre-existing kidney disease or significantly impaired kidney function; metabolites (excreted mainly in urine) may accumulate. Not studied in kidney impairment.
- Hemodialysis (intermittent)
- Avoid (label: not in pre-existing kidney disease). Not dialyzable (high protein binding). NSAIDs may hasten loss of residual kidney function.
- Peritoneal dialysis
- Avoid (label: not in pre-existing kidney disease). NSAIDs may hasten loss of residual kidney function.
- CRRT
- Avoid: NSAIDs can worsen acute kidney injury.
- Dialyzable? Unlikely: hemodialysis may not be useful because of high protein binding (label 10).
- Monitoring Kidney function before and during use in at-risk patients; stop if kidney function worsens. Potassium, blood pressure; gastrointestinal bleeding.
From the Mefenamic acid monograph (renalcarematters.com, reviewed).
Use: CYKLOKAPRON ® is indicated in patients with hemophilia for short-term use (2 to 8 days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. US FDA label
Note: Fixed-dose combinations may not allow the dose changes advised for each component; check the strength and use the single agents if a component needs adjusting.
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney dosing for each component (single-agent) is shown under Component information.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosage forms
Philippines
- Film-coated tablet: 500 mg/250 mg
Registered products in the Philippines
1 product registered with the Food and Drug Administration (FDA) Philippines list Mefenamic acid + Tranexamic acid as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
TranamicTranexamic Acid+ Mefenamic Acid | 500 mg/250 mg Film-Coated TabletAluminum Foil Strip x 6's (Box of 30's and 60's) | Rx | Concept Pharmaceuticals Ltd.India | Medethix, Inc. | DRP-10049 | Dec 2, 2029 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .